Piperlongumine suppresses growth and sensitizes pancreatic tumors to gemcitabine in a xenograft mouse model by modulating the NF-kappa B pathway

Cancer Prevention Research

Volumn 9, Issue 3, 2016, Pages 234-244

  Wang, Yongwei ^a   Wu, Xiangsong ^a   Zhou, Yinan ^a   Jiang, Hongchi ^a   Pan, Shangha ^a   Sun, Bei ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN D1; GELATINASE B; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NATURAL PRODUCT; PIPERLONGUMINE; PROTEIN BCL 2; PROTEIN BCL XL; SURVIVIN; UNCLASSIFIED DRUG; VASCULOTROPIN; X LINKED INHIBITOR OF APOPTOSIS; 1,3 DIOXOLANE DERIVATIVE; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; PIPERLONGUMININE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS ASSAY; ARTICLE; CANCER INHIBITION; CAPILLARY DENSITY; CELL PROLIFERATION; DOWN REGULATION; DRUG SENSITIZATION; DRUG STRUCTURE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; ONCOGENE C MYC; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; PIPER LONGUM; PRIORITY JOURNAL; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; COMBINATION DRUG THERAPY; DRUG EFFECTS; DRUG POTENTIATION; DRUG SCREENING; ENZYME IMMUNOASSAY; GENE EXPRESSION REGULATION; MALE; METABOLISM; NUDE MOUSE; PANCREATIC NEOPLASMS; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; DEOXYCYTIDINE; DIOXOLANES; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NF-KAPPA B; PANCREATIC NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84962567068     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-15-0306     Document Type: Article

References (50)

1. Penchev VR, Rasheed ZA, Maitra A, Matsui W. Heterogeneity and targeting of pancreatic cancer stem cells. Clin Cancer Res 2012;18:4277-84.
2. Chen S, Wang G, Niu X, Zhao J, Tan W, Wang H, et al. Combination of AZD2281 (Olaparib) and GX15-070 (Obatoclax) results in synergistic antitumor activities in preclinical models of pancreatic cancer. Cancer Lett 2014;348:20-8.
3. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
4. Wang Y, Zhou Y, Zhou H, Jia G, Liu J, Han B, et al. Pristimerin causes G1 arrest, induces apoptosis, and enhances the chemosensitivity to gemcitabine in pancreatic cancer cells. PloS ONE 2012;7:e43826.
5. Aggarwal BB. Nuclear factor-kappaB: the enemy within. Cancer Cell 2004;6:203-8.
6. Maier HJ, Schmidt-Strassburger U, Huber MA, Wiedemann EM, Beug H, Wirth T. NF-kappaB promotes epithelial-mesenchymal transition, migration and invasion ofpancreatic carcinoma cells. Cancer Lett 2010;295:214-28.
7. Liu L, Salnikov AV, Bauer N, Aleksandrowicz E, Labsch S, Nwaeburu C, et al. Triptolide reverses hypoxia-induced epithelial-mesenchymal transition and stem-like features in pancreatic cancer by NF-kappaB downregulation. Int J Cancer 2014;134:2489-503.
8. Weichert W, Boehm M, Gekeler V, Bahra M, Langrehr J, Neuhaus P, et al. High expression of RelA/p65 is associated with activation of nuclear factor-kappaB-dependent signaling in pancreatic cancer and marks a patient population with poor prognosis. Br J Cancer 2007;97:523-30.
9. Wang Y, Zhou Y, Jia G, Han B, Liu J, Teng Y, et al. Shikonin suppresses tumor growth and synergizes with gemcitabine in a pancreatic cancer xenograft model: involvement of NF-kappaB signaling pathway. Biochem Pharmacol 2014;88:322-33.
10. Liptay S, Weber CK, Ludwig L, Wagner M, Adler G, Schmid RM. Mitogenic and antiapoptotic role of constitutive NF-kappaB/Rel activity in pancreatic cancer. Int J Cancer 2003;105:735-46.
11. Greten FR, Weber CK, Greten TF, Schneider G, Wagner M, Adler G, et al. Stat3 and NF-kappaB activation prevents apoptosis in pancreatic carcinogenesis. Gastroenterology 2002;123:2052-63.
12. Holcomb B, Yip-Schneider M, Schmidt CM. The role of nuclear factor kappaB in pancreatic cancer and the clinical applications of targeted therapy. Pancreas 2008;36:225-35.
13. Diehl JA, Benzeno S. Cyclin D1 and pancreatic carcinoma: a proliferative agonist and chemotherapeutic antagonist. Clin Cancer Res 2005;11:5665-7.
14. Wang Z, Kong D, Banerjee S, Li Y, Adsay NV, Abbruzzese J, et al. Downregulation of platelet-derived growth factor-D inhibits cell growth and angiogenesis through inactivation of Notch-1 and nuclear factor-kappaB signaling. Cancer Res 2007;67:11377-85.
15. Niu J, Chang Z, Peng B, Xia Q, Lu W, Huang P, et al. Keratinocyte growth factor/fibroblast growth factor-7-regulated cell migration and invasion through activation of NF-kappaB transcription factors. J Biol Chem 2007;282:6001-11.
16. Arlt A, Gehrz A, Muerkoster S, Vorndamm J, Kruse ML, Folsch UR, et al. Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 2003;22:3243-51.
17. Fontenele JB, Leal LK, Silveira ER, Felix FH, Bezerra Felipe CF, Viana GS. Antiplatelet effects of piplartine, an alkamide isolated from Piper tuberculatum: possible involvement of cyclooxygenase blockade and antioxidant activity. J Pharm Pharmacol 2009;61:511-5.
18. Yang YC, Lee SG, Lee HK, Kim MK, Lee SH, Lee HS. A piperidine amide extracted from Piper longum L. fruit shows activity against Aedes aegypti mosquito larvae. J Agric Food Chem 2002;50:3765-7.
19. Son DJ, Kim SY, Han SS, Kim CW, Kumar S, Park BS, et al. Piperlongumine inhibits atherosclerotic plaque formation and vascular smooth muscle cell proliferation by suppressing PDGF receptor signaling. Biochem Biophys Res Commun 2012;427:349-54.
20. Cicero Bezerra Felipe F, Trajano Sousa Filho J, de Oliveira Souza LE, Alexandre Silveira J, Esdras de Andrade Uchoa D, Rocha Silveira E, et al. Piplartine, an amide alkaloid from Piper tuberculatum, presents anxiolytic and antidepressant effects in mice. Phytomedicine 2007;14:605-12.
21. Lee SA, Hong SS, Han XH, Hwang JS, Oh GJ, Lee KS, et al. Piperine from the fruits of Piper longum with inhibitory effect on monoamine oxidase and antidepressant-like activity. Chem Pharm Bull 2005;53:832-5.
22. Rao VR, Muthenna P, Shankaraiah G, Akileshwari C, Babu KH, Suresh G, et al. Synthesis and biological evaluation of new piplartine analogues as potent aldose reductase inhibitors (ARIs). Eur J Med Chem 2012;57:344-61.
23. Lee W, Yoo H, Kim JA, Lee S, Jee JG, Lee MY, et al. Barrier protective effects of piperlonguminine in LPS-induced inflammation in vitro and in vivo. Food Chem Toxicol 2013;58:149-57.
24. Glasauer A, Chandel NS. Targeting antioxidants for cancer therapy. Biochem Pharmacol 2014;92:90-101.
25. Han SS, Son DJ, Yun H, Kamberos NL, Janz S. Piperlongumine inhibits proliferation and survival of Burkitt lymphoma in vitro. Leukemia Res 2013;37:146-54.
26. Roh JL, Kim EH, Park JY, Kim JW, Kwon M, Lee BH. Piperlongumine selectively kills cancer cells and increases cisplatin antitumor activity in head and neck cancer. Oncotarget 2014;5:9227-38.
27. Gong LH, Chen XX, Wang H, Jiang QW, Pan SS, Qiu JG, et al. Piperlongumine induces apoptosis and synergizes with cisplatin or paclitaxel in human ovarian cancer cells. Oxid Med Cell Longev 2014;2014:906804.
28. Liu JM, Pan F, Li L, Liu QR, Chen Y, Xiong XX, et al. Piperlongumine selectively kills glioblastoma multiforme cells via reactive oxygen species accumulation dependent JNK and p38 activation. Biochem Biophys Res Commun 2013;437:87-93.
29. Jin HO, Lee YH, Park JA, Lee HN, Kim JH, Kim JY, et al. Piperlongumine induces cell death through ROS-mediated CHOP activation and potentiates TRAIL-induced cell death inbreast cancer cells. J Cancer Res Clin Oncol 2014;140:2039-46.
30. Ginzburg S, Golovine KV, Makhov PB, Uzzo RG, Kutikov A, Kolenko VM. Piperlongumine inhibits NF-kappaB activity and attenuates aggressive growth characteristics of prostate cancer cells. Prostate 2014;74:177-86.
31. Randhawa H, Kibble K, Zeng H, Moyer MP, Reindl KM. Activation of ERK signaling and induction of colon cancer cell death by piperlongumine. Toxicol In Vitro 2013;27:1626-33.
32. Adams DJ, Dai M, Pellegrino G, Wagner BK, Stern AM, Shamji AF, et al. Synthesis, cellular evaluation, and mechanism of action of piperlongumine analogs. Proc Natl Acad Sci U S A 2012;109:15115-20.
33. Raj L, Ide T, Gurkar AU, Foley M, Schenone M, Li X, et al. Selective killing of cancer cells by asmall molecule targeting the stress responsetoROS. Nature 2011;475:231-4.
34. Bharadwaj U, Eckols TK, Kolosov M, Kasembeli MM, Adam A, Torres D, et al. Drug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent activity against breast cancer. Oncogene 2015;34:1341-53.
35. Adams DJ, Boskovic ZV, Theriault JR, Wang AJ, Stern AM, Wagner BK, et al. Discovery of small-molecule enhancers of reactive oxygen species that are nontoxic or cause genotype-selective cell death. ACS Chem Biol 2013;8:923-9.
36. Wang Y, Wang JW, Xiao X, Shan Y, Xue B, Jiang G, et al. Piperlongumine induces autophagy by targeting p38 signaling. Cell Death Dis 2013;4:e824.
37. Jarvius M, Fryknas M, D'Arcy P, Sun C, Rickardson L, Gullbo J, et al. Piperlongumine induces inhibition of the ubiquitin-proteasomesystem in cancer cells. Biochem Biophys Res Commun 2013;431:117-23.
38. Shrivastava S, Kulkarni P, Thummuri D, Jeengar MK, Naidu VG, Alvala M, et al. Piperlongumine, an alkaloid causes inhibition of PI3 K/Akt/mTOR signaling axis to induce caspase-dependent apoptosis in human triplenegative breast cancer cells. Apoptosis 2014;19:1148-64.
39. Han JG, Gupta SC, Prasad S, Aggarwal BB. Piperlongumine chemosensitizes tumor cells through interaction with cysteine 179 of IkappaBalpha kinase, leading to suppression of NF-kappaB-regulated gene products. Mol Cancer Ther 2014;13:2422-35.
40. Wang YW, Wang SJ, Zhou YN, Pan SH, Sun B. Escin augments the efficacy of gemcitabine through down-regulationofnuclear factor-kappaB and nuclear factor-kappaB-regulated gene products in pancreatic cancer both in vitro and in vivo. J Cancer Res Clin Oncol 2012;138:785-97.
41. Cheng ZX, Sun B, Wang SJ, Gao Y, Zhang YM, Zhou HX, et al. Nuclear factor-kappaB-dependent epithelialtomesenchymal transition induced by HIF-1alpha activation in pancreatic cancer cells under hypoxic conditions. PloS ONE 2011;6:e23752.
42. Makhov P, Golovine K, Teper E, Kutikov A, Mehrazin R, Corcoran A, et al. Piperlongumine promotes autophagy via inhibition of Akt/mTOR signalling and mediates cancer cell death. Br J Cancer 2014;110:899-907.
43. Kong R, Sun B, Jiang H, Pan S, Chen H, Wang S, et al. Downregulation of nuclear factor-kappaB p65 subunit by small interfering RNA synergizes with gemcitabine to inhibit the growth of pancreatic cancer. Cancer Lett 2010;291:90-8.
44. Wang SJ, Gao Y, Chen H, Kong R, Jiang HC, Pan SH, et al. Dihydroartemisinin inactivates NF-kappaB and potentiates the anti-tumor effect of gemcitabine on pancreatic cancer both in vitro and in vivo. Cancer Lett 2010;293:99-108.
45. Harikumar KB, Kunnumakkara AB, Sethi G, Diagaradjane P, Anand P, Pandey MK, et al. Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer. Int J Cancer 2010;127:257-68.
46. Banerjee S, Zhang Y, Wang Z, Che M, Chiao PJ, Abbruzzese JL, et al. In vitro and in vivo molecular evidence of genistein action in augmenting the efficacy of cisplatin in pancreatic cancer. Int J Cancer 2007;120:906-17.
47. Kunnumakkara AB, Sung B, Ravindran J, Diagaradjane P, Deorukhkar A, Dey S, et al. Zyflamend suppresses growth and sensitizes human pancreatic tumorstogemcitabineinanorthotopic mouse modelthrough modulation of multiple targets. Int J Cancer 2012;131:E292-303.
48. Kunnumakkara AB, Sung B, Ravindran J, Diagaradjane P, Deorukhkar A, Dey S, et al. {Gamma}-tocotrienol inhibits pancreatic tumors and sensitizes them to gemcitabine treatment by modulating the inflammatory microenvironment. Cancer Res 2010;70:8695-705.
49. Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J, Aggarwal BB. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res 2007;67:3853-61.
50. Banerjee S, Wang Z, Kong D, Sarkar FH. 3, 3'-Diindolylmethane enhances chemosensitivity of multiple chemotherapeutic agents in pancreatic cancer. Cancer Res 2009;69:5592-600.